Welcome to Markets Desk, your midday read on what's moving the tape.
INmune Bio reported second quarter two thousand twenty six earnings this morning, with investors watching closely for any update on the company's neuroinflammation pipeline. The clinical-stage biotech has been under scrutiny over its trial timelines, and today's call will be parsed for any signals on commercialization runway and cash burn heading into year end.
Staying in the neuro space, Cognition Therapeutics posted a narrowed net loss for the second quarter and announced plans to launch a Phase three study of zervimesine in diffuse Lewy body disease by mid two thousand twenty seven. For a clinical-stage company, a shrinking loss alongside a concrete trial timeline is exactly the kind of double signal that keeps institutional interest alive.
Shifting to commodities, wheat is taking a meaningful hit across all three major contracts on Thursday. Chicago soft red winter is off thirteen to fourteen cents, while Kansas City hard red winter is leading the selloff, down seventeen to eighteen cents. Minneapolis spring wheat is also under pressure, suggesting broad-side weakness rather than a localized supply story — worth watching for any spillover into grain-linked equities.
That's the tape. Markets Desk, signing off the floor.
